The QUality of life Evaluation STudy (QUEST Initiative), was conducted by researchers at various universities, and was the world’s largest longitudinal clinical study investigating the quality of life and health economic impact of medicinal cannabis on patients with chronic disease.
Patients accessing medicinal cannabis generally have a range of conditions and symptoms that impact their quality of life. This clinical study set out to better understand and measure how these conditions and symptoms affect patients’ quality of life over time while they are accessing medicinal cannabis as a treatment option.
Recruitment for The QUEST Initiative has now closed.
Results from the study will be published by University of Sydney in due course and circulated to participants and their prescribing practitioners.
CANNAB RELIE.F (Medical CANNABis RELIEving pain in patients with the Fibromyalgia syndrome)
LGP is providing funding for a three-year PhD Scholarship research supervision to Southern Cross University study into treatment of Fibromyalgia syndrome (FMS) using medicinal cannabis.
This program is to study the efficacy and safety of medicinal cannabis in relieving pain and other symptoms. The three-year project includes a Phase 2 randomised controlled, double blinded, placebo-controlled clinical trial
LGP Head of Research & Innovation and clinical research , Dr Leon Warne will assist as a co-supervisor. LGP will also supply the cannabis medicines used in the study.
Curtin University Obesity Study
Little Green Pharma and Australian based Curtin University have joined forces to explore the use of medicinal cannabis treatment options for obesity and related health issues.
The research, led by Professor Marco Falasca from Curtin’s Medical School, will aim to identify one or more combinations of cannabinoids that may produce effects in the gastrointestinal tract to induce a feeling of fullness and a decrease in appetite, potentially leading to weight loss and even diabetes reversion.